May 2015, Vol. 2, No. 3
Exploring Advances in ImmunotherapyLetter to Our Readers
In this issue of Immunotherapy in Oncology (ITO), we continue to explore the many facets of immunotherapy, reaching beyond the basic science to bring you the practical implications of its usefulness. We are pleased to report that the FDA recently approved nivolumab injection, for intravenous use, for the treatment of patients with metastatic squamous nonâsmall cell lung cancer with progression on or after platinum-based chemotherapy. This is good news, as nivolumab, a PD-1 (programmed death-1 receptor) therapy, demonstrated improved overall survival in this population. In light of this advance, we present additional articles exploring the need for immunotherapy options in lung cancer, specifically âThe Need for Immunotherapeutic Approaches for Lung Cancerâ and âImmuno-Oncology Combination
Approaches for Lung Cancerâ. We will continue to explore this topic in future
issues of ITO.
Also of interest is the business side of immunotherapy. In our Interview with the Innovators feature, titled âThe Commercialization Process of Immunotherapies: An Interview with Olivier Lesueur and Rachel Laing, PhD,â we had the pleasure of talking with two experts from a consulting firm that specializes in bringing products to market. They compare the impact of immunotherapies in the current day to what chemotherapy agents were to cancer care in the 1970s. This comparison isnât lost on pharmaceutical companies, who are focused on commercializing immunotherapy agents as quickly as possible.
Also in this issue, we present articles from meetings around the country monitoring the progress of immunotherapies. From FDA approvals to biomarkers, youâll find an array of the most recent, groundbreaking events from the immunology field. We are greatly encouraged by the advances in cancer treatment that immunotherapy affords us, and it is our sincere hope this information assists you in providing the best care for your patients. We are pleased to be your source for information, and as always, we thank you for being part of our reading community.
Sanjiv S. Agarwala, MD
Editor in Chief
Immunotherapy in Oncology
A new class of cancer therapies has set its sights on immune checkpoints. A trio of studies presented at the 2015 Genitourinary Cancers Symposium offered a glimpse into the evolving landscape of treatment for metastatic renal cell carcinoma (mRCC), and the programmed death ligand 1 (PD-L1) and its receptor, programmed [ Read More ]
The Commercialization Process of Immunotherapies:
An Interview with Olivier Lesueur and Rachel Laing, PhD
The field of immunotherapy has made great strides in recent years, culminating in the FDA approvals of 3 checkpoint inhibitors: Yervoy, Keytruda, and Opdivo. For Big Pharma, this means the race is under way to investigate the potential of immunotherapies in as many indications as possible. The potential for blockbuster [ Read More ]